Optum Rx’s latest look at the drug development pipeline highlights three drugs for rare and chronic conditions that payers and plan sponsors should be watching.
Source: www.fiercehealthcare.com
IKON Portfolio Context
IKON Group Investments manages 11 portfolio companies across energy, healthcare, aviation, real estate, life sciences, and impact sectors.